Presented on June 14, 2023.
Dyne Therapeutics will present released preclinical data demonstrating that Dyne’s FORCE™ platform achieved delivery to the brain in non-human primates and robust pharmacological effects in a model of myotonic dystrophy type 1 (DM1). Click here to learn more about Dyne Therapeutics.
Each month biotechnology, pharmaceutical and academic partners, large and small, working on treatments and a cure for myotonic dystrophy will sit down with our community to share their progress and answer your questions. Click here to find all our upcoming Meet the DM Drug Developers dates!
Ashish Dugar, PhD, MBA
Chief Medical Affairs Officer
Dr. Dugar has over 20 years of broad experience across medical affairs, clinical and commercial development, and real-world evidence (RWE) generation. Prior to joining Dyne, Dr. Dugar served as vice president and global head of medical affairs at Sarepta Therapeutics, Inc., where he built the company’s medical affairs organization.
Previously, Dr. Dugar led all commercial and market access efforts for Intra-Cellular Therapies, Inc. as vice president and head of commercial development. Dr. Dugar has also held executive management roles at Roche and Pfizer. He began his career at the National Institutes of Health and holds a PhD in pharmacology from Penn State College of Medicine.
Vice President, Global Head of Patient Advocacy and KOL Engagement
Molly brings extensive experience in patient advocacy and community engagement to her role at Dyne, where she leads global patient advocacy and KOL engagement across all the company's disease focuses. She previously served as chief executive officer of the Myotonic Dystrophy Foundation, a global patient advocacy organization. In that role, she led strategic direction and administrative oversight for the comprehensive programmatic and fundraising efforts of the foundation and its staff. Molly has over 25 years of leadership-level experience building, implementing, and running award-winning domestic and international community programs for organizations in both the private and nonprofit sectors. She received her M.A. from the University of Iowa.